Imperial Oil Limited Common Stock vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Imperial Oil Limited Common Stock trades at $129.6 (market cap $62.22B), while Nuvation Bio Inc. Class A Common Stock trades at $4.72 (market cap $1.66B). The key difference: Imperial Oil Limited Common Stock is far larger — about 37.5× Nuvation Bio Inc. Class A Common Stock's market cap, and Imperial Oil Limited Common Stock pays a 1.9% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| IMO | NUVB | |
|---|---|---|
Market Cap | $62.22B | $1.66B |
Volume | 560,544 | 7,608,075 |
Sector | Energy | Health |
52-Week High | $138.33 | $9.54 |
52-Week Low | $83.72 | $3.41 |
Enterprise Value | $63.13B | $1.25B |
Dividend Yield | 1.9% | — |
Typical Hold Time | — | 6 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nuvation Bio (NUVB) trades at $4.72, down 3.67% today, with a bearish technical outlook despite strong analyst support. The biopharma company shows promising revenue growth with $170M projected for 2026 but remains unprofitable with negative margins. Recent FDA approval for IBTROZI and Fast Track designation for safusidenib provide clinical catalysts, though cash burn remains elevated with -$121M operating cash flow in 2026.
Wall Street maintains strong bullish sentiment with 80% buy ratings and $20.50 price target (334% upside), but investors face significant execution risk as the company burns cash to commercialize new oncology therapies. The stock offers high-risk, high-reward potential dependent on successful commercialization and path to profitability.
Trailing returns across standard periods
Imperial Oil Limited is a Canadian integrated energy company that explores for and produces crude oil and natural gas, operates oil sands projects at Cold Lake, Kearl, and Syncrude, and refines and markets petroleum products under the Esso and Mobil brands. ExxonMobil Corporation holds a majority ownership stake in the company.
Read more on IMO →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →